FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response
Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001. NUZ-001 is the company’s lead investigational therapy […]
FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response Read More »